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PTATE-OF-THE-ART PAPERS
merging Therapies for the
anagement of Decompensated Heart Failure
rom Bench to Bedside
mil M. deGoma, MD, Randall H. Vagelos, MD, FACC, Michael B. Fowler, MB, MRCP, FACC,
uan A. Ashley, MRCP, DPHIL
tanford, California
While pharmaceutical innovation has been highly successful in reducing mortality in chronic heart
failure, this has not been matched by similar success in decompensated heart failure syndromes.
Despite outstanding issues over definitions and end points, we argue in this paper that an
unprecedented wealth of pharmacologic innovation may soon transform the management of these
challenging patients. Agents that target contractility, such as cardiac myosin activators and novel
adenosine triphosphate-dependent transmembrane sodium-potassium pump inhibitors, provide
inotropic support without arrhythmogenic increases in cytosolic calcium or side effects of more
traditional agents. Adenosine receptor blockade may improve glomerular filtration and diuresis by
exerting a direct beneficial effect on glomerular blood flow while vasopressin antagonists promote
free water excretion without compromising renal function and may simultaneously inhibit
myocardial remodeling. Urodilatin, the renally synthesized isoform of atrial natriuretic peptide,
may improve pulmonary congestion via vasodilation and enhanced diuresis. Finally, metabolic
modulators such as perhexiline may optimize myocardial energy utilization by shifting adenosine
triphosphate production from free fatty acids to glucose, a unique and conceptually appealing
approach to the management of heart failure. These advances allow optimism not only for the
advancement of our understanding and management of decompensated heart failure syndromes
but for the translational research effort in heart failure biology in general. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.0392006;48:2397–409) © 2006 by the American College of Cardiology Foundation
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fhile recent times have witnessed great progress in reducing
he mortality associated with chronic heart failure, progress in
he management of decompensated heart failure (DHF) syn-
romes has languished, reflected by a limited therapeutic
rmamentarium and an equally sparse evidence-based litera-
ure. Initial stabilization and symptomatic improvement is
chieved in the majority of patients with available interventions
1). However, rehospitalization and mortality rates remain
igh (30% to 60%) in the months after discharge (2–4).
ithin the next decade, a wealth of research activity and
harmacologic innovation may transform how we diagnose,
lassify, treat, and evaluate patients admitted for DHF. On-
oing pre-clinical and clinical studies are evaluating novel
notropic agents, diuretics and aquaretics, and modulators of
yocardial metabolism (Fig. 1). This article provides an
verview of promising drugs in development, offering mecha-
istic insights as well as data from animal and human trials.
HALLENGES IN THE
VALUATION OF NOVEL THERAPIES
ecompensated heart failure represents an often amorphous
linical entity, a complex and heterogeneous group of syn-
romes encompassing numerous disease states with differing
From Stanford University, Stanford, California.c
Manuscript received May 18, 2006; revised manuscript received July 6, 2006,
ccepted July 31, 2006.resentations, outcomes, and optimal medical management.
ne approach to undifferentiated DHF considers several
rchetypal clinical syndromes, such as systemic volume over-
oad, low cardiac output, and acute pulmonary edema (5).
ystemic volume-overload heart failure represents a common
linical syndrome within DHF. These patients often carry a
nown diagnosis of heart failure and present with gradually
orsening symptoms and signs of fluid overload such as
dema, ascites, and dyspnea. In-hospital medical management
rincipally involves intravenous diuretics and vasodilators.
ow-output DHF is characterized by poor end-organ perfu-
ion, manifest as hypotension, altered mental status, fatigue,
nd pre-renal azotemia. Congestion may or may not be present
epending on, among other factors, the pulmonary lymphatic
apacity. Patients with this type of heart failure often require
nvasive hemodynamic monitoring and positive inotropic ther-
py. Typically older, hypertensive patients with preserved
ystolic function and acute pulmonary edema comprise a third
linical syndrome of DHF. In these cases, vasodilators fre-
uently achieve rapid resolution of symptoms. As a framework
n evolution, this approach suffers from overlapping categories
hat prohibit the strict classification of patients presenting with
eatures of more than one clinical syndrome, ultimately hin-
ering its ability to guide management. Furthermore, the
resent method does not address differences between heart
ailure etiologies, a distinction that may prove critical for
ertain therapies, such as modulators of myocyte metabolism.
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Emerging Therapies for DHF December 19, 2006:2397–409nother approach to differentiate DHF patients relies upon
isk stratification, employing hemodynamic variables and lab-
ratory values such as systolic blood pressure, blood urea
itrogen, and serum creatinine to identify groups at high risk
or morbidity and mortality (6).
The absence of effective short-term surrogate end points
oses another major challenge to evaluating new drugs for the
anagement of DHF syndromes. Improved hemodynamic
arameters, readily available measures in the inpatient setting,
o not reliably translate into improved clinical outcomes longer
erm. Administration of nesiritide, for example, yields statisti-
ally significant improvements in pulmonary capillary wedge
ressure (PCWP) and cardiac index at 6 h (7). However,
ecent meta-analyses suggest that nesiritide use may be asso-
iated with adverse events. One study observed a 52% (95%
onfidence interval [CI] 1.16 to 2.00) increase in the risk of
orsening renal function, while another revealed a 74% (95%
I 0.97 to 3.12) increase in mortality at 30 days compared with
on–inotrope-based control therapy (8,9). Although firm con-
lusions await the results of randomized, controlled studies, the
ndings are in contrast with the acute hemodynamic benefit
bserved with nesiritide infusion. Identifying convenient,
hort-term surrogate markers that accurately predict longer-
erm prognosis would facilitate the assessment and expedite the
evelopment of pharmacotherapies for DHF. The recent
EVIVE (Randomized Multicenter Evaluation of Intrave-
ous Levosimendan Efficacy) trials were some of the first to
ttempt a clinical composite end point that could account for
he complex nature of DHF presentations, dividing patients
nto “better,” “worse,” or “unchanged” groups according to
everal variables. While this end point approximated the more
bjective plasma brain natriuretic peptide (BNP) measure-
ent, it did not account for the greater number of adverse
rrhythmic events or the higher mortality seen in the levosi-
endan group, leaving the question as to the ideal end point
or such trials unanswered.
NOTROPIC THERAPIES
ugmenting systolic function with positive inotropic phar-
acotherapy may be an appropriate management objective
Abbreviations and Acronyms
ANP  atrial natriuretic peptide
ATP  adenosine triphosphate
AVP  arginine vasopressin
BNP  brain natriuretic peptide
cAMP  cyclic adenosine monophosphate
CI  confidence interval
DHF  decompensated heart failure
FFA  free fatty acid
LTCC  L-type calcium channel
NYHA  New York Heart Association
PCWP  pulmonary capillary wedge pressure
PKA  protein kinase A
RyR  ryanodine receptorn selected patients presenting with low-output DHF. gmong current generation inotropic agents, heightened
nergy utilization and the coupling of contractility, chro-
otropy, and calcium represent significant limitations. First,
rugs available to enhance contractility may induce mal-
daptive remodeling by imposing increasing metabolic de-
ands on the failing heart. An open-label randomized study
evealed a trend towards worsened 6-month survival after
n-hospital infusion of dobutamine compared with nesirit-
de. Novel drugs targeting cardiac energetics as a means to
mprove systolic function are discussed in the following text
see the Metabolic Modulation section). Second, tachyar-
hythmias contribute to the excess morbidity and mortality
bserved in clinical trials using available inotropic agents
10). Dopamine, dobutamine, epinephrine, and milrinone
ncrease cyclic adenosine monophosphate (cAMP) levels
ithin cardiac myocytes, resulting in activation of the
AMP-dependent protein kinase A (PKA) and phosphor-
lation of 2 key calcium channels, the L-type calcium
hannel (LTCC) and the ryanodine receptor (RyR) (11,12).
ocated on the myocyte cell membrane, LTCC mediates
alcium entry from the extracellular space during the plateau
hase, or phase 2, of the non-pacemaker myocyte action
otential. In a process called calcium-induced calcium
elease, calcium influx via LTCC stimulates calcium release
rom sarcoplasmic reticulum stores by binding to the cal-
ium receptor/calcium channel RyR located on the sarco-
lasmic reticulum. Protein-kinase-A–mediated phosphory-
ation of LTCC and RyR induces conformational changes
n both transmembrane channels promoting calcium flux
nto the cystol. The rise in cystosolic calcium concentration
romotes actin-myosin cross-bridging by displacing the
nhibitory troponin-tropomyosin complex and results in
yocyte shortening. However, the added contractility
omes at a price—accumulation of calcium is arrhythmo-
enic, accounting for one possible mechanism for inducing
elayed afterdepolarizations and triggered activity (13,14).
Despite the aforementioned considerations, data from the
DHERE (Acute Decompensated Heart Failure National
egistry) indicate relatively frequent use of available inotro-
ic agents, with milrinone or dobutamine administered to
0% of patients hospitalized for DHF (15). Importantly, the
ajority of these patients lacked evidence of hemodynamic
ompromise—only 10% manifest hypotension, 30% had
mpaired renal function, and 30% to 40% experienced
yspnea at rest—suggesting perhaps overenthusiastic use of
notropic therapy. Developing drugs that improve myocyte
ontractility without perturbing the cellular electrophysio-
ogical balance remains an elusive goal in the management
f DHF. Two novel therapies attempting to dissociate
notropy and arrhythmogenicity are cardiac myosin activa-
ors and istaroxime.
ARDIAC MYOSIN ACTIVATORS
ardiac myosin activators directly target the force-
enerating cardiac enzyme, myocardial myosin ATPase,
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December 19, 2006:2397–409 Emerging Therapies for DHFccelerating its activity in order to enhance contractility.
olecular events underlying muscle contraction begin with
inding of adenosine triphosphate (ATP) to the globular
ead domain of myosin, resulting in its dissociation from
igure 1. Overview of emerging pharmacotherapies for the management o
quaporin-2; AVP arginine vasopressin; cAMP cyclic adenosine monoph
ransferase-1; Gs stimulatory G-protein; Na/K-ATPase adenosine tripho
. Illustration by Rob Flewell.ctin (16,17) (Fig. 2). Rapid hydrolysis of ATP to adenosine siphosphate and phosphate induces flexion of the myosin
ead. Upon release of phosphate, conformational changes in
he myosin head result in a high-affinity interaction with the
djacent actin unit. Extension of the myosin head—the
te decompensated heart failure. ADP  adenosine diphosphate; AQP 
te; cGMP cyclic guanosine monophosphate; CPT-1 carnitine palmitoyl
-dependent transmembrane sodium-potassium pump; PKA protein kinasef acu
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Emerging Therapies for DHF December 19, 2006:2397–409f actin by approximately 10 nm. The cycle then concludes
n the rigor state after adenosine diphosphate leaves its
inding cleft.
Several small molecules have been developed that
arget myocardial myosin ATPase, including CK-
689705, CK-1122534, CK-1213296, and CK-1827452.
n vitro and in vivo studies using rat and dog models of
eart failure demonstrate that these novel agents increase
ractional shortening of ventricular myocytes in a dose-
ependent manner without altering intracellular calcium
evels (18–22). Beta-blockade does not abrogate the
notropic effect, supporting a mechanism of action inde-
endent of adrenergic activation (18). Transient kinetic
nalysis of individual steps in the cardiac myosin cycle
eveal that these compounds accelerate the rate-limiting,
hird step of the enzymatic process, hastening the tran-
ition of myosin from the weakly filament-bound to the
trongly filament-bound state (23). An intravenous for-
ulation of CK-1827452 is currently in phase I clinical
evelopment as a potential treatment for patients with
HF. While cardiac myosin activators provide a mech-
nism for decoupling contractility and chronotropy, it
emains unclear whether fueling an accelerated myosin
TPase cycle will incur a significant metabolic cost. If so,
he accompanying increased oxygen consumption may
igure 2. The myosin ATPase cycle. Cardiac myosin activators appear to ac
lament-bound to the strongly filament-bound state. ADP  adenosine diphave a detrimental effect on the failing heart. (STAROXIME: Na/K-ATPase INHIBITOR
staroxime (PST-2744), a novel Na/K-ATPase inhibitor
hemically unrelated to cardiac glycosides, augments myo-
ardial contractility by stimulating calcium entry via the
arcolemmal Na/Ca-exchanger. In vitro and in vivo analyses
f istaroxime therapy in guinea pigs and dogs revealed
ose-dependent increases in inotropic activity as measured
y the maximum rate of pressure rise in the left ventricle
dP/dtmax) (24,25). Unlike available inotropic therapies,
owever, preliminary data suggest that istaroxime may
ermit cytosolic calcium accumulation while avoiding a
roarrhythmic state. Compared with digoxin, istaroxime
emonstrated a significantly greater ratio of proarrhythmic
ose to inotropic dose as well as a more rapid onset and
ecay of effect, suggesting both a wider margin of safety and
more predictable pharmacokinetic profile. Another study
ompared istaroxime and dobutamine in a canine model of
hronic ischemic heart failure (26). The change in dP/dtmax
fter treatment was equivalent between subjects adminis-
ered istaroxime and dobutamine (51%) (Fig. 3); however,
eak heart rate was significantly higher with dobutamine
nfusion (160 vs. 120 beats/min). Measurements of cardiac
utput were not obtained. In cardiomyopathic hamsters, istar-
xime improved survival as well as contractility and lusitropy
te the rate-limiting step, hastening the transition of myosin from the weakly
te; ATP  adenosine triphosphate. Illustration by Rob Flewell.27). Untreated mortality at 52 weeks of age was 100%,
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December 19, 2006:2397–409 Emerging Therapies for DHFompared with 54% among hamsters administered istaroxime.
lthough encouraging, the exact mechanism by which istar-
xime achieves uncoupling of calcium and arrhythmogenicity
emains unclear. Electrophysiologic studies in guinea pig ven-
ricular myocytes suggest one possible mechanism: suppression
f the transient inward calcium current directly involved in the
enesis of delayed afterdepolarizations (28).While studies have
een promising to date, istaroxime remains in the early stages
f pre-clinical research.
IURETICS, AQUARETICS, AND NATRIURETICS
onventional diuretics such as loop and thiazide diuretics
emain the mainstay of therapy for the management of fluid
verload in both systemic volume overload and acute pul-
onary edema DHF, administered to 87% of hospitalized
atients according to the national ADHERE registry (29).
owever, these drug classes suffer from inherent limita-
ions, achieving water loss via excretion of solute at the
xpense of glomerular filtration. Impaired glomerular filtra-
ion mediated by loop diuretics arises from indirect sequelae
f volume depletion as well as direct detrimental effects on
ephron function, including decreased glomerular blood
ow. Adenosine receptor blockade may overcome this
imitation, achieving diuresis and maintaining glomerular
ltration by improving renal blood flow. The second mech-
nistic disadvantage described in the preceding text, solute-
riven volume loss, results in hyponatremia and hypokale-
ia. Numerous studies suggest that these metabolic
erangements have profound clinical significance, either as
he cause of morbidity and mortality or as surrogate markers
or poor outcomes (30–32). Furthermore, by inhibiting
odium transport in the macula densa (33), loop diuretics
uch as furosemide directly activate the renin-angiotensin-
ldosterone system (34–37) responsible for cardiac remod-
igure 3. Change in left ventricular dP/dtmax comparing istaroxime (PST-
744) to dobutamine in 5 dogs with chronic ischemic heart failure. No
ifference was found between PST-2744 and 5 g/kg/min dobutamine.
oth significantly increased dP/dtmax (p  0.05). Reproduced with
ermission (26).ling and the progression of heart failure (38). Novel Aasopressin receptor antagonists, on the other hand, pro-
ote solute-free water diuresis, or aquaresis, and may,
herefore, correct hypervolemia while simultaneously pre-
erving an appropriate electrolyte milieu and minimizing
enin release (39). Finally, a number of atrial natriuretic
eptide (ANP) analogues are under active investigation,
ncluding urodilatin. While nesiritide, or recombinant
-type natriuretic peptide, significantly reduces PCWP via
ulmonary vasodilation and diuresis (7,40), meta-analyses
f randomized, controlled trials suggest a possible associa-
ion with worsened renal function and an increased risk of
eath (8,9). Ongoing clinical studies attempt to clarify the
ffects of nesiritide and explore other natriuretic peptides for
he management of pulmonary and systemic congestion.
eripherally inserted veno-venous ultrafiltration, as a me-
hanical approach to fluid overload, lies beyond the scope of
ur pharmacotherapeutic discussion, and promising results
rom recent trials have been reviewed elsewhere (41–43).
DENOSINE ANTAGONISTS
our distinct receptor subtypes—A1, A2a, A2b, and A3—
ediate the effects of adenosine on the kidney, heart, and
lood vessels (44). Current research efforts in the manage-
ent of DHF focus on the beneficial effects of A1-receptor
lockade on renal blood flow. Inhibition of adenosine
athways in the kidney does not target tubular function, but
ather improves glomerular filtration by exerting a direct
eneficial effect on glomerular blood flow and interrupting
ubuloglomerular feedback (44,45). Stimulation of renal
1-receptors induces afferent arteriolar constriction (46),
ost-glomerular vasodilation (47), and mediates tubuloglo-
erular feedback, the macula densa mechanism by which
ncreased sodium delivery to the proximal tubule leads to
ecreased glomerular filtration rate (48). Selective A1-
eceptor blockade attenuates these potentially detrimental
ffects in animal and human studies, suggesting a potential
herapeutic role in the treatment of DHF.
In a rat model of dilated cardiomyopathy, administration
f BG-9719, a selective A1-receptor antagonist, achieved
iuresis while maintaining stable renal and cardiac function
49). When added to chronic furosemide therapy, BG-9719
ugmented renal blood flow and glomerular filtration rate.
imilarly, BG-9719 doubled urine output and increased
reatinine clearance in pigs with rapid pacing-induced
ystolic dysfunction (50). Invasive hemodynamic monitor-
ng in pigs treated with BG-9719 revealed significantly
ecreased PCWPs without adverse effects on cardiac out-
ut, mean arterial pressure, or heart rate.
Human studies of adenosine antagonists in heart failure
ave also yielded promising results. In one crossover trial
omparing furosemide and BG-9719, both agents induced
atriuresis in 12 patients with New York Heart Association
NYHA) functional class III or IV heart failure, but only
G-9719 preserved baseline glomerular filtration rate (51).
nother study examined the renal activity of BG-9719
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Emerging Therapies for DHF December 19, 2006:2397–409lone and in combination with 80 mg of intravenous
urosemide in 63 patients admitted with symptomatic heart
ailure (25). Patients were deemed eligible for the random-
zed, placebo-controlled, double-blind trial provided they
ere categorized as NYHA functional class II, III, or IV,
ad a documented ejection fraction less than or equal to
0%, and remained edematous despite a daily furosemide
ose of at least 80 mg. The trial examined three BG-9719
osing regimens, 7-h infusions designed to yield serum
oncentrations of 0.1, 0.75, or 2.5 g/ml. BG-9719 alone
ripled urine output compared with placebo without effect-
ng a decrease in glomerular filtration rate or potassium loss
Fig. 4). Furosemide alone augmented urine output 8-fold
hile significantly reducing glomerular filtration rate. BG-
719 added to intravenous furosemide further increased
iuresis and, more importantly, reversed the decline in renal
unction such that no difference in glomerular filtration rate
as observed between the combination and placebo groups.
Despite the diuretic advantages of renal A1-receptor
lockade, the complexity of adenosine physiology necessi-
ates further trials to prove that adenosine antagonism yields
o adverse clinical consequences. In an apparent pharma-
ologic paradox, A1-receptor agonists are simultaneously
nder development as cardioprotective therapy in heart
ailure. Activation of cardiac A1-receptors inhibits norepi-
ephrine and endothelin release and may thereby antago-
ize neurohormonal axes involved in myocardial hypertro-
hy and remodeling (52). In a murine model of pressure
verload heart failure, administration of 2-chloroadenosine,
selective A1-receptor agonist, attenuated cardiac hyper-
rophy, pulmonary edema, and systolic dysfunction induced
y transverse aortic constriction (53). In addition, adenosine
as been identified as a critical trigger substance for isch-
mic pre-conditioning (54). Sublethal ischemia increases
yocardial levels of adenosine, which, via stimulation of
1- and A3-receptors, triggers an intracellular cascade
onferring a protected phenotype resistant to further isch-
mic insult. If A1-receptors on myocardial cells indeed serve
significant cardioprotective role, therapeutic inhibition of
he A1-receptor in DHF may require renal specificity to
chieve diuresis without compromising cardiac function.
igure 4. Adenosine antagonist BG9719 augments diuresis and preservest
lomerular filtration rate (GFR) when administered alone or in combina-
ion without furosemide. Reproduced with permission (25).ASOPRESSIN ANTAGONISTS
rginine vasopressin (AVP), also known as antidiuretic
ormone, is critical to the regulation of fluid balance,
ugments vascular tone in heart failure, and may play a role
n myocardial remodeling (55). Arginine vasopressin exerts
ts cardiorenal effects through 2 receptor subtypes (56).
2-receptors located on renal collecting duct principal cells
ediate the primary physiologic action of AVP, free water
eabsorption (55). Binding of AVP to V2-receptors stimu-
ates the synthesis of aquaporin-2 water channel proteins
nd promotes their transport to the apical surface (Fig. 5).
t the cell membrane, aquaporin-2 permits selective free
ater reabsorption down the medullary osmotic gradient,
ltimately decreasing serum osmolarity and increasing fluid
alance. V1a-receptors on peripheral arterial and coronary
mooth muscle cells effect cAMP-independent vasocon-
triction, explaining the utility of AVP in shock states (57).
he functional significance of V1a-receptors on cardiomy-
cytes remains unclear. In animal models, stimulation of
his receptor population promotes fibroblast proliferation
nd protein synthesis, suggesting a role in myocardial
ypertrophy and remodeling (58–61).
Patients with heart failure consistently exhibit elevated
irculating levels of AVP in proportion to disease severity
34,61–65). In the SOLVD (Studies of Left Ventricular
ysfunction) trial, plasma levels of AVP, along with renin
nd norepinephrine, were significantly higher in patients
ith left ventricular dysfunction compared with control
ubjects, and higher still in patients with overt DHF (34).
s with other neurohormonal axes in heart failure, activa-
ion of the AVP pathway is hypothesized to represent a
aladaptive response leading to worsened congestive symp-
oms and ultimately disease progression. Impaired systolic
unction and depressed cardiac output activate pressure-
ensitive baroreceptors in the carotid artery, which, in turn,
timulate AVP release from the posterior pituitary (38).
2-receptor-mediated aquaporin-2 expression promotes
ree water reabsorption, aggravating the existing fluid im-
alance (66–69). In addition to inappropriate volume re-
ention, AVP may worsen hemodynamics in heart failure.
ntravenous AVP infusion in patients with chronic heart
ailure augmented systemic vascular resistance, decreased
ardiac output, and increased PCWP in a dose-dependent
ashion, presumably as a result of V1a-receptor–mediated
asoconstriction (56,70). Growing evidence suggests that
VP itself, not simply its attendant abnormal loading
onditions, may effect structural changes in the myocardium
ia V1a-receptor activation. When administered to cultured
at cardiomyocytes, AVP stimulated protein synthesis and
broblast proliferation (58–61,71,72). Selective V1a-
eceptor antagonism abrogated these effects and, in one in
ivo study of myocardial infarcted rats, prevented deterio-
ation in systolic function (73). In human heart failure and
emodeling, the pathophysiologic significance of AVP and
he myocyte V1a-receptor subpopulation remain undeter-
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December 19, 2006:2397–409 Emerging Therapies for DHFined. The posited harmful effects of excess AVP in heart
ailure provide the rationale for the development of AVP
ntagonists as novel therapeutic agents for the management
f DHF (74).
Tolvaptan (OPC-41061) is a selective V2-receptor an-
agonist, binding 29 times more avidly to V2-receptors than
o V1a-receptors (75). In the rat model, oral administration
f tolvaptan achieved significant and sustained dose-
ependent aquaresis without affecting serum concentrations
f sodium or creatinine (75). Equipotent doses of furo-
emide, however, decreased serum sodium concentration
nd increased serum creatinine concentration (76). More-
ver, while the loop diuretic augmented renin activity and
irculating levels of aldosterone, no such activation of the
enin-angiotensin-aldosterone axis was noted in rats treated
ith tolvaptan (76). The ACTIV in CHF (Acute and
hronic Therapeutic Impact of a Vasopressin Antagonist in
ongestive Heart Failure) trial evaluated the effects of
olvaptan in patients hospitalized with DHF and a systolic
jection fraction less than 40% (77). At randomization,
ean ejection fraction was 24%, and all subjects were
YHA functional class III or IV. Adding tolvaptan to
tandard therapy significantly increased mean 24-h urine
olume (Fig. 6) and decreased body weight compared with
lacebo. Despite these aquaretic benefits, administration of
olvaptan was not associated with an improvement in the
rimary combined clinical end point, defined as death,
ospitalization for heart failure, or unscheduled presenta-
ion for heart failure requiring escalation of therapy. With
egard to adverse events, sudden cardiac death was observed
n 5 patients treated with tolvaptan and 1 patient in the
igure 5. Vasopressin (AVP) stimulates synthesis of aquaporin-2 (AQP)
ater channel proteins and their transport to the apical surface of collecting
uct principal cells. Other abbreviations as in Figure 1. Illustration by Rob
lewell.lacebo group. A large phase III trial, EVEREST (Efficacy
p
df Vasopressin Antagonism in Heart Failure: Outcome
tudy with Tolvaptan), is underway to further examine the
ffect of tolvaptan on cardiovascular mortality and heart
ailure hospitalization (78). Limited information exists re-
arding the effects of V2-receptor blockade on renal hemo-
ynamics and neurohormonal activity in patients with heart
ailure. A recent crossover study of 14 patients demonstrated
hat tolvaptan, unlike furosemide, did not impair renal
lood flow or increase renin activity and circulating norepi-
ephrine levels (79). In addition to tolvaptan, other selective
2-receptor antagonists currently undergoing clinical inves-
igation include SR-121463 and AVPA-985 (55,80).
Simultaneous blockade of V1a- and V2-receptors would
heoretically yield advantages over V2-receptor antagonism,
amely, inhibition of V1a-mediated arterial vasoconstric-
ion and myocardial remodeling (59,60,81). Conivaptan
YM087) is a dual antagonist demonstrating 10 times the
ffinity for V1a-receptors compared with V2-receptors (55).
n experimental models of ischemic and non-ischemic heart
ailure, conivaptan achieved significant aquaresis while de-
reasing systemic vascular resistance and improving systolic
unction (82–84). Selective V2-receptor blockade alone did
ot augment cardiac performance. As noted in the preced-
ng text, conivaptan inhibited AVP-induced protein synthe-
is in the rat cardiomyocyte model, suggesting a potential
herapeutic role in the inhibition of myocardial hypertrophy
59,85). To date, few trials have examined the effects of
onivaptan in congestive heart failure patients. One short-
erm study enrolled patients with symptomatic systolic heart
ailure on appropriate therapy including a loop diuretic,
ngiotensin-converting enzyme inhibitor, and beta-blocker
86). At randomization, mean ejection fraction was 23%,
nd the majority of subjects were classified as NYHA
unctional class III. Conivaptan significantly increased urine
igure 6. Tolvaptan therapy increased 24-h urine volume compared with
lacebo in patients hospitalized for decompensated heart failure. Repro-
uced with permission (77).
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Emerging Therapies for DHF December 19, 2006:2397–409utput in a dose-dependent manner compared with placebo
nd reduced PCWP and right atrial pressure. Adverse
vents occurred less frequently after acute conivaptan ther-
py compared with placebo. Notably, systemic vascular
esistance and cardiac index were not different between the
onivaptan and placebo groups. Baseline levels of AVP were
ow in the study population, potentially masking a vasodi-
atory benefit of V1a-receptor inhibition. Patients hospital-
zed for DHF and, in particular, patients administered
2-receptor antagonists exhibit higher AVP levels that may
rovoke undesired vasoconstriction. Hemodynamic conse-
uences of V1a/V2-receptor antagonists as well as their
ffects on myocardial remodeling require further elucidation
n long-term studies, ideally comparing dual V1a/V2- and
elective V2-receptor blockade. The ADVANCE (A Dose
valuation of a Vasopressin Antagonist in CHF undergoing
xercise) trial is currently examining the effect of conivaptan
n functional capacity, measured by peak oxygen consump-
ion, in patients with heart failure (87).
RODILATIN (ULARITIDE)
trial, or A-type, natriuretic peptide is synthesized in
pecialized atrial myoendocrine cells as the prohormone
NP-(1-126), processed into the biologically active 28-
mino acid ANP-(99-126), and released into the circulation
n response to atrial stretch (88). Binding to natriuretic
eptide type A receptors activates coupled guanylate cyclase
nd stimulates the formation of cyclic guanosine mono-
hosphate. Downstream pathways effect peripheral vasodi-
atation and inhibit renal sodium reabsorption. Administra-
ion of intravenous ANP in pre-clinical and clinical studies
ecreases PCWP and systemic vascular resistance, reduces
lasma levels of renin and aldosterone, and increases urine
utput (89,90). However, the hemodynamic and neurohor-
onal benefits of ANP are blunted in DHF patients
ompared with normal subjects (90). Mechanisms of im-
aired ANP response in heart failure include down-
egulation of ANP receptors and increased activity of
eutral endopeptidase, the enzyme responsible for ANP
egradation (91).
In 1988, a unique, renally synthesized isoform of ANP
as isolated from human urine (92). Distal tubular cells
roduce the 32-amino acid ANP, termed urodilatin, and
ecrete the peptide into the tubular lumen, where it travels
o the inner medullary-collecting duct and binds to natri-
retic peptide type A receptors to promote sodium excretion
88). Unlike ANP-(99-126), the active circulating isoform,
rodilatin possesses a TAPR-NH3 terminal extension that
onfers resistance to biological inactivation by neutral en-
opeptidase. Both experimental animal models and early
linical trials demonstrated therapeutic effects of urodilatin,
hich significantly enhanced diuresis and natriuresis and
educed PCWP and systemic vascular resistance to a greater
xtent than ANP-(99-126) (93–100). aPharmacologic application of urodilatin to the management
f DHF began with the evaluation of ularitide, its synthetic
quivalent, in the SIRIUS (Safety and Efficacy of an Intrave-
ous Placebo-Controlled Randomized Infusion of Ularitide in
Prospective Double-blind Study in Patients with Symptom-
tic, Decompensated Chronic Heart Failure) trial (101). The
andomized, double-blind, placebo-controlled study examined
he effects of 24-h ularitide infusion in the setting of DHF.
he study population consisted of 24 patients with NYHA
unctional class III to IV symptoms, a mean cardiac index of
.9 l/min/m2, and a mean PCWP of 26 mm Hg without
vidence of cardiogenic shock. The benefits of higher doses of
laritide, 30 ng/kg/min, included early significant decreases in
CWP compared with placebo, later decreased N-terminal
ro-BNP compared with baseline, a trend towards decreased
ystemic vascular resistance and increased cardiac index, im-
roved dyspnea self-assessment scores, and an apparent de-
reased need for diuretic and nitrate therapy (Fig. 7). Hemo-
ynamic improvements, however, were transient, failing to
ersist throughout the 24-h drug infusion, and at many time
oints did not achieve statistical significance compared with
lacebo. Moreover, the administration of ularitide at 30 ng/
g/min effected significant reductions in systolic blood pres-
ure, averaging 17 mm Hg, after 6 h. To clarify the safety and
fficacy of ularitide, a larger trial aptly named SIRIUS II
nrolled 221 patients presenting with DHF (102). Compared
ith placebo, 24-h infusion of ularitide at 15 and 30 ng/kg/
in achieved significant increases in cardiac index and de-
reases in systemic vascular resistance starting at 1 h after
nitiation of therapy and persisting over 24 h. At these doses,
laritide also significantly reduced N-terminal pro-BNP at
4 h compared with placebo but did not alter 30-day survival
r improve renal function. As in SIRIUS I, however, ularitide
roduced a dose-dependent decrease in systolic blood pressure,
ith 16% of patients in the 30 ng/kg/min group experiencing
ypotension.
Ongoing concerns regarding the safety and efficacy of
nother natriuretic peptide, nesiritide, provide pause for
hought regarding more detailed study of ularitide (8,9,103).
s noted above, short-term improvements in hemodynamic
arameters alone are no longer felt to be sufficient to support
linical use. In addition, the rationale behind supplementing
neurohormonal system that is already maximally up-
egulated endogenously has yet to be proven. Additional
tudies are required to establish safety as well as a therapeu-
ic benefit in terms of clinical end points. Recently, a
arge-scale, multicenter trial has been proposed using an
ntermediate dose of ularitide, 15 ng/kg/min, in an attempt
o improve congestive symptoms and signs in patients with
HF.
ETABOLIC MODULATION
ptimizing myocardial energy utilization represents a
nique and conceptually appealing approach to the man-
gement of heart failure. In the normal adult human heart,
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December 19, 2006:2397–409 Emerging Therapies for DHFhe majority (60% to 90%) of ATP production results from
ree fatty acid (FFA) metabolism, with only 10% to 40% of
yocardial energy generated by glucose (104,105). Utiliza-
ion of FFAs is ordinarily advantageous, providing more
TP per gram of metabolic fuel than carbohydrate catab-
lism. However, under ischemic conditions with oxygen as
he limiting substrate, glycolysis becomes the more efficient
athway, requiring 10% to 15% less oxygen compared with
FA breakdown (105,106) (Table 1). Furthermore, FFA
xidation during ischemia inhibits pyruvate dehydrogenase,
esulting in increased conversion of pyruvate to lactate,
rogressive tissue acidosis, and impaired myocyte contrac-
igure 7. Changes from baseline during 24-h placebo or urodilatin infusion,
nd after discontinuation. *p 0.05 versus placebo; †p 0.05 versus baseline.
T-pro-BNP  N-terminal pro-B-type natriuretic peptide; PCWP 
ulmonary capillary wedge pressure; RAP right atrial pressure. Reproduced
ith permission (101).ility (107–111). In principle, shifting energy utilization Arom FFAs to glucose would optimize metabolic efficiency,
everse abnormalities in the cellular milieu, and improve
ardiac function.
ERHEXILINE
ttempts at therapeutic metabolic manipulation were first
pplied to the symptomatic relief of angina, frequently with
triking effect. First discovered in the 1960s, perhexiline, the
ost extensively studied modulator of myocyte energetics,
romotes glucose utilization through inhibition of carnitine
almitoyl transferase-1, an enzyme critical to mitochondrial
ptake of FFAs (104). Several randomized studies demon-
trated that perhexiline use at doses of 100 to 200 mg twice
aily achieved reductions exceeding 50% in the frequency of
nginal episodes and the use of sublingual nitroglycerin, as
ell as significant improvements in exercise tolerance (112–
16). Treatment with perhexiline yielded benefits even
mong patients with recurrent angina despite maximal
edical management with beta-blockers, nitrates, and
alcium-channel blockers. In one randomized, double-
lind, placebo-controlled trial of 17 patients with refractory
ngina on combination therapy, 65% of patients adminis-
ered perhexiline for 3 months noted improvements in
schemic symptoms during exercise, compared with 18% of
atients given placebo (117).
In the 1970s and 1980s, reports of hepatotoxicity and
eripheral neuropathy with long-term perhexiline use tem-
ered initial enthusiasm for the novel antianginal agent
118–121). Toxicity arises as a result of phospholipid
ccumulation mediated by carnitine palmitoyl transferase
nhibition, which occurs primarily among patients with
lowed hepatic metabolism (CYP2D6) of perhexiline (122–
28). Further studies demonstrated that cautious dose
itration to maintain plasma concentrations between 150 to
00 ng/ml appears to avoid serious adverse sequelae (129).
ost-marketing surveillance data from Australia reveal a
ramatic decline in the incidence of peripheral neuropathy
nd hepatitis with the advent of therapeutic monitoring
130). Nonetheless, perhexiline use remains restricted to
evere, refractory ischemic symptoms, and its availability
urrently limited to Australia, New Zealand, and several
uropean countries (104).
The improved safety profile provided by therapeutic
onitoring has prompted renewed interest in perhexiline, in
articular in another metabolically stressed state, heart
ailure. In theory, optimization of cardiac energetics would
enefit not only ischemic, but non-ischemic cardiomyopa-
hy. Numerous studies in heart failure patients without
able 1. The Theoretical ATP Yield of Complete Oxidation of
lucose and the Free Fatty Acid Palmitate
Substrate
Substrate Efficiency
(mol ATP/mol Substrate)
Oxygen Efficiency
(mol ATP/mol O)
lucose 36 3.0
almitate 129 2.6TP  adenosine triphosphate.
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Emerging Therapies for DHF December 19, 2006:2397–409ignificant coronary artery disease have revealed regional
yocardial hypoperfusion, attributed to increased oxygen
emand from tachycardia and heightened wall stress and
ecreased oxygen supply due to endothelial dysfunction and
levated filling pressures (131–133).
While no study has yet examined the utility of perhexiline
n patients hospitalized for DHF, one small, short-term
linical trial suggests a significant benefit in patients with
hronic heart failure (134). Fifty-six optimally medicated
atients with ischemic or non-ischemic heart failure, left
entricular ejection fraction 40%, and NYHA functional
lass II or III symptoms were randomized to receive
erhexiline or placebo. Serial measurements of blood per-
exiline levels guided dose titration to prevent toxicity, with
goal concentration of 0.15 to 0.59 ml/l. After 8 weeks,
erhexiline-treated ischemic and non-ischemic groups dem-
nstrated a 43% relative increase in left ventricular ejection
raction (absolute 10 percentage points) and 17% increase in
eak exercise oxygen consumption (Fig. 8). In comparison,
rior studies have shown an increase in peak exercise oxygen
onsumption of 13% to 20% associated with angiotensin-
onverting enzyme inhibitor therapy (135) and 8% with
iventricular pacing (136). Perhexiline increased peak sys-
olic velocity at rest and maximal dobutamine stress by 15%
igure 8. Effect of perhexiline treatment on peak exercise oxygen con-
umption (VO2 max) and left ventricular ejection fraction (LVEF) in
ongestive heart failure patients. p 0.001 in both cases. Reproduced with
ermission (134).nd 25%, respectively, and significantly improved quality of
ife as measured by the Minnesota Living with Heart
ailure Questionnaire. Administration of placebo was not
ssociated with improvements in any of the pre-specified
linical end points. Adverse events were infrequent and
imited to transient nausea and dizziness, with no cases of
epatotoxicity or peripheral neuropathy observed. Although
imited in size and duration, this study advances the
ypothesis that an innovative therapeutic mechanism—
etabolic modulation—may potentially serve as a future
reatment of heart failure of either ischemic or non-ischemic
tiology. In addition to perhexiline, other agents directed at
ptimizing myocyte energetics include trimetazidine, rano-
azine, and etomoxir (104).
UMMARY
hile some have decried the absence of pharmacologic
nnovation in heart failure, we argue in this paper that there
s cause for optimism. New inotropic agents may avoid
rrhythmia by directly targeting cardiac myosin. Novel
a/K-ATPase inhibitors may augment myocardial contrac-
ility without the adverse effect profile of cardiac glycosides.
denosine receptor blockade may improve glomerular fil-
ration and diuresis by exerting a direct beneficial effect on
lomerular blood flow. Vasopressin antagonists promote
ree water excretion without compromising renal function
nd may simultaneously inhibit myocardial remodeling.
ovel natriuretic peptides may improve pulmonary conges-
ion via vasodilation and enhanced diuresis. Metabolic
odulators may optimize myocardial energy utilization by
hifting ATP production from FFAs to glucose.
While debate as to the exact nature and definition of
HF syndromes will undoubtedly continue, and while the
ost appropriate end point in acute heart failure clinical
rials will remain the subject of many editorials to come, we
emonstrate here that even as these issues are resolving, the
ipeline of pharmacologic innovation continues to offer us
ew hope that short-term improvements in hemodynamics,
olume status, and clinical symptoms can lead ultimately to
he holy grail of improved outcome for our patients.
eprint requests and correspondence: Dr. Euan A. Ashley,
ivision of Cardiovascular Medicine, Falk CVRC, Stanford Uni-
ersity, 300 Pasteur Drive, Stanford, California 94305. E-mail:
uan@stanford.edu.
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